You are here

Lynparza

Ovarian Cancer Market Still Up For Grabs

Ovarian Cancer Market Still Up For Grabs

Barron's

Clovis Oncology

Flag link:

Watch out Tesaro, AstraZeneca and Merck get FDA OK for broad use of Lynparza

Watch out Tesaro, AstraZeneca and Merck get FDA OK for broad use of Lynparza

Endpoints

Flag link:

AstraZeneca, Merck team up on Lynparza combos in collaboration worth up to $8.5B

AstraZeneca, Merck team up on Lynparza combos in collaboration worth up to $8.5B

Fierce Pharma

Flag link:

AstraZeneca Is Focused on Lynparza’s Label Expansion in 2017

AstraZeneca Is Focused on Lynparza’s Label Expansion in 2017

Market Realist

BRCA-mutated ovarian cancer

Flag link:

New test may turn AZ's Lynparza into precision drug for prostate cancer

New test may turn AZ's Lynparza into precision drug for prostate cancer

Yahoo/Reuters

prostate cancer

Flag link:

ASCO17: AstraZeneca pumps up expectations on near-term cancer drug wins, looking to shed a rep for failure

ASCO17: AstraZeneca pumps up expectations on near-term cancer drug wins, looking to shed a rep for failure

Endpoints

Flag link:

AstraZeneca's Lynparza Slows Breast Cancer Caused By BRCA Mutations By 42%

AstraZeneca's Lynparza Slows Breast Cancer Caused By BRCA Mutations By 42%

Forbes

BRCA-mutant breast cancer

Flag link:

AstraZeneca Shares Progress on LYNPARZA™ (olaparib) Tablets in the US

AstraZeneca Shares Progress on LYNPARZA™ (olaparib) Tablets in the US

Yahoo

Flag link:

AZ gears up for FDA filing as PARP inhibitor Lynparza wins big in ovarian cancer trial

AZ gears up for FDA filing as PARP inhibitor Lynparza wins big in ovarian cancer trial

Fierce Pharma

PARP inhibitors

clinical trials

Flag link:

Clovis, Tesaro Soar on Astrazeneca Phase Three News

Clovis, Tesaro Soar on Astrazeneca Phase Three News

TheStreet.com

Clovis Oncology

clinical trials

Flag link:

AstraZeneca Stock Rises On Successful Breast Cancer Drug Trial

AstraZeneca Stock Rises On Successful Breast Cancer Drug Trial

TheStreet.com

Flag link:

Clovis Falls on Fears Ovarian Cancer Drug Inferior to Competition

Clovis Falls on Fears Ovarian Cancer Drug Inferior to Competition

TheStreet.com

Clovis Oncology

Flag link:

An Overnight Double! Could These Drugmakers Be Next?

An Overnight Double! Could These Drugmakers Be Next?

Motley Fool

PARP inhibitors

Clovis Oncology

Flag link:

LYNPARZA (olaparib): Latest Data Suggest Potential Overall Survival Advantage in Patients with Platinum Sensitive Ovarian Cancer

LYNPARZA (olaparib): Latest Data Suggest Potential Overall Survival Advantage in Patients with Platinum Sensitive Ovarian Cancer

Yahoo

Flag link:

AstraZeneca looks to DNA damage-response drugs for edge in oncology

AstraZeneca looks to DNA damage-response drugs for edge in oncology

BioPharma Dive

Flag link:

AstraZeneca chief chalks up milestones on his map to $45B

AstraZeneca chief chalks up milestones on his map to $45B

Fierce Pharma

Flag link:

AstraZeneca's olaparib looks promising for a targeted set of prostate cancer patients

AstraZeneca's olaparib looks promising for a targeted set of prostate cancer patients

Fierce Biotech

prostate cancer

Flag link:

AstraZeneca Has An Oncology Pipeline Packed With Potential

AstraZeneca Has An Oncology Pipeline Packed With Potential

Seeking Alpha

Flag link:

Clovis Wins One ASCO '15 Battle, Loses Another, Against Rival AstraZeneca

Clovis Wins One ASCO '15 Battle, Loses Another, Against Rival AstraZeneca

TheStreet.com

Clovis Oncology

Flag link:

Lynparza, First In A New Class Of Cancer Drugs, Is Surprisingly Active In A Wide Range Of Tumors

Lynparza, First In A New Class Of Cancer Drugs, Is Surprisingly Active In A Wide Range Of Tumors

Forbes

Flag link: